![Page 1: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/1.jpg)
INVESTIGATOR RESPONSIBILITIES
March 2015
![Page 2: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/2.jpg)
Objectives
Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations and guidelines.
Responsibilities and commitments associated with signing the FDA Form 1572. (For non-IND studies, the DAIDS Investigator of Record Form applies instead of FDA Form 1572.)
Financial disclosure requirements.
Impact of protocol noncompliance.
Oversight responsibilities related to the informed consent process, drug accountability, safety monitoring, maintaining essential study documents and delegation of responsibilities.
![Page 3: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/3.jpg)
![Page 4: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/4.jpg)
What Does This Mean? The FDA’s focus is on the Principal Investigator
listed on FDA Form 1572.
For DAIDS-funded trials, this is the Investigator of Record or (IoR).
Others in the DAIDS structure/chain of command (such as the CTU PI or CRS Leader) will not be important at the time of the audit. It is the IoR who is answerable for the execution of the protocol.
![Page 5: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/5.jpg)
Investigator Responsibilities Ensure that the clinical investigation is
conducted according to the approved protocol and in compliance with all relevant sections of the U.S. Code of Federal Regulations (CFR), ICH-GCP standards, and in-country regulations and guidelines.
Protect the rights, safety and welfare of subjects.
![Page 6: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/6.jpg)
Investigator Responsibilities: Regulations and Guidances Investigator responsibilities are specifically
described in: ICH E6 (Sections 4.0 and 8.0).
U.S. Code of Federal Regulations (CFR).
U.S. FDA Guidance – Investigator Responsibilities (October 2009).
U.S. FDA Guidance– Q&A Form FDA 1572 (May 2010).
FDA Form 1572 / DAIDS IoR Form.
![Page 7: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/7.jpg)
ICH E6: Good Clinical Practice:Consolidated Guideline
Published as official guidance in U.S. Federal Register in 1997
Objective: to provide a unified standard for the
EU, Japan, U.S. to facilitate mutual
acceptance of clinical data by the regulatory
authorities
![Page 8: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/8.jpg)
ICH E6 GCP – Section 4.0 Investigator Responsibilities
Investigator’s Qualifications and Agreements
Adequate Resources
Medical Care of Trial Subjects
Communications with IRB/IEC
Compliance with Protocol
Investigational Product(s)
Randomization Procedures and Unblinding
Informed Consent of Trial Subjects
Records and Reports
Progress Reports
Safety Reporting
Premature Termination or Suspension of a Trial
Final Report(s) by Investigator
4.1
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
4.10
4.11
4.12
4.13
![Page 9: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/9.jpg)
Country-Specific Requirements
This presentation reviews the U.S. federal requirements for the clinical Investigator.
All local and country-level requirements must also be met.
Contact your local IRB/IEC or CTU PI for additional information on these.
![Page 10: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/10.jpg)
FDA Clarification of Investigator Responsibilities Supervision of the
conduct of the clinical investigation.
Delegation of tasks to study staff.
Training of study staff.
Supervision of staff to whom tasks are delegated.
Reporting protocol deviations.
Supervision of third parties (if applicable).
Protection of the rights, safety and welfare of participants in clinical trials.
Provision of reasonable medical care.
Provide reasonable access to medical care.
![Page 11: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/11.jpg)
Review of FDA Form 1572
![Page 12: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/12.jpg)
Form FDA 1572
• Include screen shot here.
![Page 13: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/13.jpg)
By Signing Form 1572… The Investigator is agreeing that he or she will
personally conduct or supervise the described investigations.
To do this, the Investigator must be intimately involved with the study. Depending on the size of the staff, the qualifications of the staff members, and the complexity of the protocol(s), this involvement may vary according to the site and protocol.
The Investigator must have a full understanding of the protocol, as well as stay informed of all participant and site issues.
The Investigator should ensure procedures are established to escalate issues quickly when needed.
![Page 14: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/14.jpg)
FDA Form 1572:Eight Investigator Commitments
Maintain protocol adherence
Personally conduct or supervise
Ensure informed consent of subjects
Report adverse experiences
Provide training to sub-investigators
Ensure adequate and accurate recordkeeping
Ensure proper IRB/IEC review and reporting
Comply with all regulatory requirements
![Page 15: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/15.jpg)
Who Should be Listed as a Sub-Investigator on the 1572?
The decision to list an individual as a sub-investigator depends on his/her level of responsibility-- whether he/she is performing significant clinical, investigation-related duties.
In general, if an individual is directly involved in the performance of procedures required by the protocol, and the collection of data, that person should be listed on the 1572.
It is not necessary to include someone with only an occasional or ancillary role.
![Page 16: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/16.jpg)
When to Update the 1572(U.S. Federal Regulation)
According to U.S. federal regulation, the FDA Form 1572 must only be updated when a new protocol has been added to the IND or a new Investigator is added to the study. However, …
![Page 17: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/17.jpg)
When to Update the 1572(DAIDS Protocol Registration Manual) Within 30 days of any change in information, such
as:
The Investigator of Record changes.
A sub-investigator is added to the study or removed.
At the time of continuing IRB/IEC review (if required by the local IRB/IEC).
A laboratory is added, removed or changed.
Site location added, removed or changed.
![Page 18: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/18.jpg)
Investigator of Record Form
[Insert page 1 of Investigator of Record Form]
![Page 19: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/19.jpg)
Requirement for Investigators and Sub-Investigators to File Financial Disclosure Forms
![Page 20: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/20.jpg)
Reporting Financial Interests Goal: preserve objectivity of clinical research
and the protection of human subjects
Regulation: 21 CFR 54
Requirement: each clinical investigator must disclose any financial interests that may be affected by the outcome of the research or attest to the absence of relevant significant financial interests
![Page 21: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/21.jpg)
Specific Requirement
Per 21 CFR 54, each clinical research Investigator and sub-investigator (anyone listed on the FDA Form 1572 for the study) is required to disclose the aggregated financial interests of themselves, their spouse and dependent children, as they relate to the study sponsor and/or study product(s).
![Page 22: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/22.jpg)
When to Report: 4 Time Points1. When an Investigator or sub-investigator
is first added to the FDA Form 1572 or DAIDS IoR Form.
2. Within thirty (30) days of discovering that relevant changes to their significant financial interests have occurred (during the conduct of the study and for one year following).
(continued on next slide)
![Page 23: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/23.jpg)
When to Report: 4 Time Points (continued from last slide)
3. At the completion of all study-specific activities, that is, the date of the last follow-up for the study at that site.
4. At any additional times specified by the study sponsor.
![Page 24: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/24.jpg)
How to Report Financial Disclosure A study-specific, Financial
Disclosure Form can be found on the MTN website (www.mtnstopshiv.org) - Study Implementation Materials.
Definition of reportable financial interests (as per 21 CFR 54) and instructions for completion of the form will appear on the form itself.
![Page 25: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/25.jpg)
Steps to Report Financial Disclosure Print the study-specific, Financial Disclosure
Form from www.mtnstopshiv.org.
Complete the form – remember to sign and date it.
Email a scanned copy of the completed, signed and dated form to the FHI 360 CRM for the trial.
File the original, completed, signed and dated form in the study binder with the associated 1572 form.
![Page 26: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/26.jpg)
How are Conflicts Managed?
All financial disclosure statements will be reviewed by the Leadership & Operations Center (LOC).
If potential conflicts of interest are identified, the LOC, in conjunction with the Investigator, will determine if steps need to be taken to minimize the potential for bias.
![Page 27: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/27.jpg)
ICH E6 – Section 4.0 Investigator Responsibilities
Investigator’s Qualifications and Agreements
Adequate Resources
Medical Care of Trial Subjects
Communications with IRB/IEC
Compliance with Protocol
Investigational Product(s)
Randomization Procedures and Unblinding
Informed Consent of Trial Subjects
Records and Reports
Progress Reports
Safety Reporting
Premature Termination or Suspension of a Trial
Final Report(s) by Investigator
4.1
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
4.10
4.11
4.12
4.13
![Page 28: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/28.jpg)
Compliance with the ProtocolICH E6 Section 4.5
FDA Form 1572
21 CFR 312.60
21 CFR 812.100
![Page 29: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/29.jpg)
Protocol Compliance
The Investigator is expected to make every effort to ensure that the trial is conducted in compliance with the protocol approved by the IRB/IEC.
The IoR’s dated signature on the protocol signature page confirms this agreement.
![Page 30: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/30.jpg)
Protocol Compliance
The Investigator agrees that he or she “will not make any changes in the research without IRB/IEC approval, except where necessary to eliminate apparent immediate hazards to human subjects” (see FDA Form 1572).
![Page 31: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/31.jpg)
Protocol Compliance Any departure from the protocol must be
documented as a protocol deviation.
In the event you find a deviation has occurred at your site, follow the instructions provided to you in the DAIDS Source Documentation policy, the Protocol SSP and by the FHI 360 CRM for documenting deviations and making corrections.
![Page 32: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/32.jpg)
Deviations from the Protocol
Recognizing that protocol deviations do sometimes occur, it is important to promptly document and report them.
Why is it critical that this happens?
![Page 33: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/33.jpg)
Potential Impact of Noncompliance
• Impact on risk to the participant
• Impact on data quality
• Impact on scientific integrity and credibility
• Rejection of data by regulatory bodies
• Selection of the site for FDA Inspection
• Disqualification of the Investigator
• Suspension of site activities
![Page 34: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/34.jpg)
Risks for Noncompliance Insufficient investigator involvement in study conduct.
Poor supervision and training of study staff.
Inappropriate delegation of study tasks to unqualified persons.
Overworked investigator and study staff (e.g., too many subjects, complex study with large data collection, too many concurrent studies).
Failure to adequate protect study subjects.
![Page 35: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/35.jpg)
ICH E6 – Section 4.0Investigator Responsibilities
Investigator’s Qualifications and Agreements
Adequate Resources
Medical Care of Trial Subjects
Communications with IRB/IEC
Compliance with Protocol
Investigational Product(s)
Randomization Procedures and Unblinding
Informed Consent of Trial Subjects
Records and Reports
Progress Reports
Safety Reporting
Premature Termination or Suspension of a Trial
Final Report(s) by Investigator
4.1
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
4.10
4.11
4.12
4.13
![Page 36: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/36.jpg)
Role of the Investigator in Ensuring Informed Consent and Some Consenting Challenges
Declaration of Helsinki
ICH E6 Section 4.8
FDA Form 1572
21 CFR 50
![Page 37: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/37.jpg)
Discuss study, risk/benefits, etc.
Update participants
Allow time for understandingAssess understanding
and willingness
Ensure comprehensionEnsure comprehensionEncourage questionsEncourage questions
Provide informed consent form
The Consenting Process
![Page 38: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/38.jpg)
Key Points of the Informed Consent Process
Translation
Role of the witness
Timing
Signing/Dating
Version
Re-signing the consent
![Page 39: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/39.jpg)
What are the consenting challenges? What strategies could you use to mitigate
challenges?
Consenting a Vulnerable Population – Illiterate Participants
![Page 40: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/40.jpg)
Consider asking potential participants to read the informed consent form (ICF) out loud.
Test writing skills.
Read the informed consent form to the participant.
Ask participant to “teach back”.
Illiterate Participants
![Page 41: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/41.jpg)
ICH E6 – Section 4.0Investigator Responsibilities
Investigator’s Qualifications and Agreements
Adequate Resources
Medical Care of Trial Subjects
Communications with IRB/IEC
Compliance with Protocol
Investigational Product(s)
Randomization Procedures and Unblinding
Informed Consent of Trial Subjects
Records and Reports
Progress Reports
Safety Reporting
Premature Termination or Suspension of a Trial
Final Report(s) by Investigator
4.1
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
4.10
4.11
4.12
4.13
![Page 42: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/42.jpg)
Investigational Study Product(s)
ICH E6 Section 4.6
21 CFR 312.57(a)
21 CFR 312.62(a)
![Page 43: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/43.jpg)
Responsibility for investigational product accountability lies with the Investigator/institution.
Some or all of these duties can be delegated to the pharmacist or other individual who is under the supervision of the Investigator.
The product should be stored as specified by the sponsor and in accordance with regulatory requirements.
Investigational Study Product
![Page 44: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/44.jpg)
Investigator or designee should ensure products are only used in accordance with the approved protocol.
The Investigator or designee should explain the correct use of the product and should check throughout the trial that each participant is following instructions properly.
Investigational Study Product
![Page 45: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/45.jpg)
Product Accountability Records These records should include the
following information:
Product delivery to the trial site. Inventory at the site. Use by each subject. Return to the sponsor or alternative
disposition of unused product. Dates, quantities, batch/serial numbers,
expiration dates (if applicable), unique code assigned to the product and trial participant.
![Page 46: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/46.jpg)
ICH E6 – Section 4.0Investigator Responsibilities
Investigator’s Qualifications and Agreements
Adequate Resources
Medical Care of Trial Subjects
Communications with IRB/IEC
Compliance with Protocol
Investigational Product(s)
Randomization Procedures and Unblinding
Informed Consent of Trial Subjects
Records and Reports
Progress Reports
Safety Reporting
Premature Termination or Suspension of a Trial
Final Report(s) by Investigator
4.1
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
4.10
4.11
4.12
4.13
![Page 47: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/47.jpg)
Medical Care of Trial Subjects and Safety ReportingICH E6 Sections 4.3 and 4.11
DAIDS Expedited Adverse Events Reporting Policy, DWD-POL-CL-013.03
![Page 48: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/48.jpg)
Medical Care of Trial Subjects A qualified physician must be responsible for all
trial-related medical decisions and ensure medical care is provided for any AEs while in the trial.
It is recommended that the Investigator inform the participant’s primary physician about trial participation, if the participant agrees.
The Investigator should attempt to find the reason for premature withdrawal of participation in the trial when appropriate.
![Page 49: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/49.jpg)
Safety Reporting All SAEs should be reported to DAIDS per the
EAE Reporting Manual. PTIDs (not names or other unique identifiers) should be used in these reports.
AEs should be reported according to the requirements of the protocol.
Investigator must follow the site’s IRB/IEC requirements regarding reporting AEs, EAEs, SAEs and unanticipated problems to the IRB/IEC.
![Page 50: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/50.jpg)
ICH E6 – Section 4.0Investigator Responsibilities
Investigator’s Qualifications and Agreements
Adequate Resources
Medical Care of Trial Subjects
Communications with IRB/IEC
Compliance with Protocol
Investigational Product(s)
Randomization Procedures and Unblinding
Informed Consent of Trial Subjects
Records and Reports
Progress Reports
Safety Reporting
Premature Termination or Suspension of a Trial
Final Report(s) by Investigator
4.1
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
4.10
4.11
4.12
4.13
![Page 51: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/51.jpg)
Essential DocumentsICH E6 Section 4.9 and 8.0
![Page 52: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/52.jpg)
Essential Study Documents ICH-GCP Section 8.0 provides a clear and
orderly presentation of those documents required to be kept on-file at the Clinical Research Site (CRS) by the Investigator of Record.
These documents, individually and collectively, permit evaluation of the conduct of the trial and the quality of the data produced.
![Page 53: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/53.jpg)
Essential Study Documents
Filing essential documents at the CRS in a timely manner can greatly assist in the successful management of a trial by the Investigator.
These documents may be audited by the sponsor's independent audit function and inspected by regulatory authorities.
![Page 54: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/54.jpg)
ICH E6 – Section 4.0Investigator Responsibilities
Investigator’s Qualifications and Agreements
Adequate Resources
Medical Care of Trial Subjects
Communications with IRB/IEC
Compliance with Protocol
Investigational Product(s)
Randomization Procedures and Unblinding
Informed Consent of Trial Subjects
Records and Reports
Progress Reports
Safety Reporting
Premature Termination or Suspension of a Trial
Final Report(s) by Investigator
4.1
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
4.10
4.11
4.12
4.13
![Page 55: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/55.jpg)
Site Oversight
![Page 56: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/56.jpg)
How is Oversight Assessed? Were those to whom tasks were delegated
qualified to do the tasks?
Did staff received adequate training to perform the delegated tasks?
Is there evidence demonstrating the ongoing involvement of the IoR?
Was there adequate supervision of any third parties?
![Page 57: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/57.jpg)
Demonstrating Adequate Oversight
Availability of sub-investigator CVs.
Maintenance of training records.
Timely signature/initials/date of IoR on study documents.
Delegation of Authority Log (DoA).
![Page 58: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/58.jpg)
Study Delegation of Authority Log(continued on next slide)
[Insert page 1 of study Delegation of Authority Log (DoA)]
![Page 59: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/59.jpg)
Study Delegation of Authority Log
[Insert page 2 of study Delegation of Authority Log (DoA)]
![Page 60: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/60.jpg)
References
ICH E6
U.S. FDA Form 1572
DAIDS IoR Form
U.S. Code of Federal Regulations (CFR)
U.S. FDA Guidance – Investigator’s Responsibilities, (October 2009)
![Page 61: INVESTIGATOR RESPONSIBILITIES March 2015. Objectives Review and Discuss: Responsibilities of the clinical research Investigator as per relevant regulations](https://reader035.vdocument.in/reader035/viewer/2022062409/5697bfd31a28abf838cabfe2/html5/thumbnails/61.jpg)
References
U.S. FDA Guidance– Q&A Form FDA 1572 (May 2010)
DAIDS Policy: Requirements for Source Documentation, DWD-POL-CL-04.00 and DWD-POL-CL-04.00A1
DAIDS Expedited Adverse Events Reporting Policy, DWD-POL-CL-013.03